Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;20(7):411-412.
doi: 10.1038/s41575-023-00744-9.

Positioning therapies for the management of inflammatory bowel disease

Siddharth Singh  1
Affiliations

Positioning therapies for the management of inflammatory bowel disease

Siddharth Singh. Nat Rev Gastroenterol Hepatol. 2023 Jul.
No abstract available

PubMed Disclaimer

References

    1. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870–1880 (2012). - DOI - PubMed
    1. Baumgart, D. C. & Le Berre, C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N. Engl. J. Med. 385, 1302–1315 (2021). - DOI - PubMed
    1. Singh, S. et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 6, 1002–1014 (2021). - DOI - PubMed - PMC
    1. Solitano, V. et al. Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 (2022). - DOI - PubMed
    1. Burr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976–1987 (2022). - DOI

MeSH terms

LinkOut - more resources